DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for restrictive dermopathy — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleRestrictive dermopathy maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for restrictive dermopathy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
zinc metallopeptidase STE24 (ZMPSTE24) — ZMPSTE24 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet pc1drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4AW6 · 3.4 Å · ligand 1,2-DIACYL-SN-GLYCERO-3-PHOSPHOCHOLINE (PC1). Experimental structure, not a prediction.
What the evidence adds up to
Restrictive dermopathy is a lethal genetic disorder that is uniformly fatal in the neonatal period. The 2010 review notes that about 60 cases had been described by that time, while the 2008 report puts the figure at fewer than 50. The 2018 authors suggest the condition may not be as rare as previously believed, reporting two cases from a single centre within two years. The disease is characterised by taut, translucent, rigid skin with prominent superficial vessels, generalised joint contractures, distinctive facial features including low-set ears, micrognathia, and a fixed open O-shaped mouth, intrauterine growth retardation, and pulmonary hypoplasia. Skin biopsy shows a thick epidermis, thin dermis, abnormally arranged collagen bundles, poorly developed appendages, and near absence of dermal elastic fibres.
Most cases are caused by autosomal recessive mutations in ZMPSTE24, and less frequently by autosomal dominant mutations in LMNA. The 2010 paper identified compound heterozygous frameshifting mutations in exon 1 (c.50delA) and exon 5 (c.584_585delAT) of ZMPSTE24 in one affected sibling, confirming autosomal recessive inheritance through parental analysis. The 1993 study found that fibroblasts from one affected infant showed increased expression of the alpha-1 and alpha-2 integrin subunits responsible for collagen binding, which was not matrix dependent. The authors interpreted this as supporting the hypothesis that restrictive dermopathy is a disorder of skin differentiation.
No treatment is described in any of these reports. The exact pathogenetic mechanisms remain unknown, as stated in the 2008 review. The genetic or developmental defects leading to the syndrome were not known at the time of the 1992 paper, and the 2010 review adds only the identification of specific mutations without addressing mechanism. What is still missing is any understanding of how ZMPSTE24 or LMNA mutations produce the skin phenotype, any animal model that could be used to test interventions, and any attempt to stratify patients by mutation type or integrin expression pattern. No funding for drug repurposing or preclinical work is mentioned in these abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics Part A · 2010 · 48 citations
Novel frameshifting mutations of the <i>ZMPSTE24</i> gene in two siblings affected with restrictive dermopathy and review of the mutations described in the literature
AbstractRestrictive dermopathy (RD) is a rare, severe, lethal genodermatosis in which tautness of the skin causes fetal akinesia or hypokinesia deformation sequence. To date, about 60 cases of RD were described. The signs of the disease are very characteristic and include intrauterine growth retardation, thin, tightly adherent translucent skin, superficial vessels, typical facial dysmorphism as well as generalized joint contractures. The syndrome is caused in most cases by ZMPSTE24 autosomal recessive mutations, or, less frequently, by LMNA autosomal dominant mutations. We report on two brothers affected with RD, who died in the neonatal period. Molecular analyses were performed in the second child, for whom biological material was available, and both parents. Compound heterozygous frameshifting mutations were identified in exon 1 (c.50delA) and exon 5 (c.584_585delAT) of the ZMPSTE24 gene. The autosomal recessive inheritance was confirmed by the parents' genomic analysis. Besides, a review of the mutations causing RD is made.
Abstract<h3>• Background.—</h3> Restrictive dermopathy is a lethal genetic disorder consisting of abnormally tight skin, generalized joint contractures, distinctive facies, and pulmonary hypoplasia. Autosomal recessive inheritance has been suggested based on multiply affected siblings and some reports of parental consanguinity. This article describes two siblings with the restrictive dermopathy syndrome and reviews previously reported cases. <h3>Observations.—</h3> Eight other cases have been reported in the literature as restrictive dermopathy. These cases have shared striking similarities in their clinical histories and phenotypes. The skin in these infants has been described as rigid and tense, with skin biopsy specimens showing a thick epidermis, thin dermis, abnormally arranged collagen bundles, and poorly developed appendages. Other prominent features are flexion contractures and craniofacial and pulmonary abnormalities. The genetic and/or developmental defects leading to the restrictive dermopathy syndrome are presently not known. <h3>Conclusions.—</h3> The restrictive dermopathy syndrome is distinct and is easily differentiated from other congenital diseases such as the icthyoses and also from the clinical conditions of sclerema neonatorum and subcutaneous fat necrosis of the newborn. Recognition of this syndrome is important for determining the prognosis of affected infants and for recommending genetic counseling to affected families. (<i>Arch Dermatol.</i>1992;128:228-231)
Fetal and Pediatric Pathology · 2008 · 22 citations
RESTRICTIVE DERMOPATHY: REPORT AND REVIEW
AbstractRestrictive dermopathy is a rare autosomal recessive disorder characterized by extreme tautness of the skin causing restricted intrauterine movement and a fetal akinesia deformation sequence. It is uniformly mostly neonatally fatal. The diagnostic findings are skin tautness with near absence of the dermal elastic fibers, usually with no or only minor anomalies of the internal organs. The exact pathogenetic mechanisms are still not known. Fewer than 50 cases have been reported. We report on a case of restrictive dermopathy and discuss the differential diagnoses.
Indian Journal of Paediatric Dermatology · 2018 · 2 citations · open access
Restrictive dermopathy: Report of two cases
AbstractRestrictive dermopathy is a rare entity that is fatal in the neonatal period itself. The rigidity of the skin leads to erosions, contractures, and restriction of respiratory movements. Diagnosis is often made clinically with classical features such as low-set ears, micrognathia, small, and persistently open fixed “o”-shaped mouth, translucent, shiny, rigid skin with prominent superficial blood vessels, and pseudocontractures of limb joints. We report two cases of restrictive dermopathy observed in our center within 2 years period and suggest that this condition may not be as rare as believed.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
